Phase I Dose Escalation Study on Bicalutamide, an Androgen Receptor Antagonist, as a Radiosensitizer Combining With Brain Re-irradiation to Treat Recurrent/Progressive Glioblastoma/High Grade Glioma
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Bicalutamide (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions
Most Recent Events
- 06 Feb 2025 Planned End Date changed from 1 Jan 2027 to 1 May 2027.
- 06 Feb 2025 Planned primary completion date changed from 1 Jul 2026 to 1 Jan 2027.
- 06 Feb 2025 Planned initiation date changed from 1 Jan 2025 to 1 May 2025.